Progyny, Inc. (PGNY)

Market Cap	1.44B -28.5%
Revenue (ttm)	1.29B +10.4%
Net Income	58.52M +7.7%
EPS	0.65 +14.0%
Shares Out	81.90M
PE Ratio	27.11
Forward PE	9.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,995,421
Open	17.67
Previous Close	17.79
Day's Range	17.26 - 17.84
52-Week Range	16.76 - 28.75
Beta	1.01
Analysts	Buy
Price Target	27.60 (+56.64%)
Earnings Date	Feb 26, 2026

About PGNY

Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management s...

• Industry: Healthcare Plans
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 680
• Stock Exchange: NASDAQ
• Ticker Symbol: PGNY
• Website: https://www.progyny.com

Financial Performance

In 2025, Progyny's revenue was $1.29 billion, an increase of 10.40% compared to the previous year's $1.17 billion. Earnings were $58.52 million, an increase of 7.70%.

Analyst Summary

According to 10 analysts, the average rating for PGNY stock is "Buy." The 12-month stock price target is $27.6, which is an increase of 56.64% from the latest price.

Price Target

$27.6

(56.64% upside)

Analyst Consensus: Buy